ANGIODYNAMICS $ANGO Q1’27 EARNINGS HIGHLIGHTS
🔹 Revenue: $80.9M (Est. $80.5M) 🟢; +6.9% YoY
🔹 Adj. EPS: -$0.04 (Est. -$0.11) 🟢
🔹 Gross Margin: 59.4%; +410 bps YoY
Affirms FY27 Guide:
🔹 Revenue: $336.0M-$341.0M (Est. $337M) 🟡
🔹 Adj. EPS: -$0.29--$0.24 (Est. -$0.27) 🟡
🔹 Adj. EBITDA: $13.0M-$16.0M (Est. $13.8M) 🟡
🔹 Gross Margin: 54% to 55%
🔹 Med Tech Growth: 12% to 15%
🔹 Med Device Growth: Flat
Cash Flow:
🔹 Cash from Operations: $15.3M used
Segment Net Revenue:
🔹 Med Tech: $39.9M; +13.2% YoY
🔹 Med Device: $41.0M; +1.4% YoY
🔹 Auryon: $18.9M; +14.7% YoY
🔹 Mechanical Thrombectomy: $12.0M; +6.7% YoY
🔹 NanoKnife: $8.3M; +29.0% YoY
Announcements:
🔹 CEO: Eric Honroth appointed effective November 2, 2026
🔹 FDA IDE approval for the RELIEF study evaluating NanoKnife IRE for benign prostatic hyperplasia
Other Q1 Metrics:
🔹 Adj. EBITDA: $5.0M (Est. $1.3M) 🟢; +127% YoY
🔹 Cash: $34.0M; debt-free balance sheet
Comments:
🔸 “Med Tech again led our growth, highlighted by Auryon's 21(st) consecutive quarter of double-digit atherectomy growth, continued performance in Mechanical Thrombectomy, and ongoing strength in our NanoKnife oncology platform.”
🔸 “I'm pleased to share that Eric Honroth will become our next President and Chief Executive Officer. He brings the right experience and leadership to build on the foundation we've established, and I will remain closely involved to ensure a smooth transition.”